Loading clinical trials...
Loading clinical trials...
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
Conditions
Interventions
Electroporation
HPV DNA Plasmids Therapeutic Vaccine VGX-3100
+1 more
Locations
8
United States
University of California, San Francisco
San Francisco, California, United States
Grady Health System
Atlanta, Georgia, United States
Anal Dysplasia Clinic MidWest
Chicago, Illinois, United States
Boston Medical Center
Boston, Massachusetts, United States
Laser Surgery Care
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Start Date
September 21, 2018
Primary Completion Date
December 31, 2024
Completion Date
June 17, 2025
Last Updated
July 16, 2025
NCT05266898
NCT06327568
NCT03051516
NCT05858021
NCT00503581
NCT01651949
Lead Sponsor
AIDS Malignancy Consortium
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions